Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Outcomes Following Salvage Therapy in Primary Refractory Peripheral T-Cell Lymphoma (PTCL)

Janie Y Zhang, MD, Robert Briski, BS, Sumana Devata, MD, Mark S Kaminski, MD, Tycel Phillips, MD, Tera Mayer, NP, Nathanael G Bailey, MD, Ryan A Wilcox, MD PhD

Blood (2016) 128 (22): 4152.

https://doi.org/10.1182/blood.V128.22.4152.4152

Published: 2016

Journal Articles

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Tycel Phillips, MD, Rod Ramchandren, MD, Michael S Wertheim, MD, Martin E Gutierrez, MD, William J Edenfield, MD, Fitzroy Dawkins, MD, Doug J DeMarini, Li Zhou, PhD, Swamy Yeleswaram, PhD, Robert C Newton, PhD, Xuejun Chen, PhD, Andres Forero-Torres, MD

Blood (2016) 128 (22): 4195.

https://doi.org/10.1182/blood.V128.22.4195.4195

Published: 2016

Journal Articles

Functional Analyses of V-Atpase Mutations in Follicular Lymphoma

Fangyang Wang, Damian Gatica, Zhang Xiao Ying, Luke F. Peterson, Denzil Bernard, Kamlai Saiya-Cork, Shaomeng Wang, Alfred Chang, Mark S Kaminski, MD, Tycel Phillips, MD, Daniel Klionsky, Sami N. Malek

Blood (2016) 128 (22): 1762.

https://doi.org/10.1182/blood.V128.22.1762.1762

Published: 2016

Journal Articles

Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study

Michael Wang, MD, Peter Martin, MD, Tycel Phillips, MD, Andre Goy, MD, Izidore S Lossos, MD, Simon A. Rule, MD, Mehdi Hamadani, MD, Nilanjan Ghosh, MD PhD, Craig B. Reeder, MD, Evelyn Barnett, Marie-Laure Casadebaig Bravo, MSc, Stephen J. Schuster, MD

Blood (2016) 128 (22): 1786.

https://doi.org/10.1182/blood.V128.22.1786.1786

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Tycel Phillips, MD, Mark Brunvand, MD, Andy Chen, MD PhD, Oliver Press, MD PhD, James Essell, MD, Annalisa Chiappella, MD, Catherine Diefenbach, MD, Surai Jones, MS Biostat, Jamie Hirata, PharmD, Ian W. Flinn, MD PhD

Blood (2016) 128 (22): 622.

https://doi.org/10.1182/blood.V128.22.622.622

Published: 2016

Journal Articles

Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL

Wyndham H. Wilson, MD PhD, Leslie L. Popplewell, MD, Tycel Phillips, MD, Amy S. Kimball, MD PhD, Saurabh Chhabra, MD, Jerry Ping, PhD, Jutta Neuenburg, MD, Nora Cavazos, MD, Louis M Staudt, MD, Sven de Vos, MD PhD

Blood (2015) 126 (23): 1527.

https://doi.org/10.1182/blood.V126.23.1527.1527

Published: 2015

NARROW

Outcomes Following Salvage Therapy in Primary Refractory Peripheral T-Cell Lymphoma (PTCL)

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Functional Analyses of V-Atpase Mutations in Follicular Lymphoma

Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL

Email alerts

ASH Publications

American Society of Hematology

Outcomes Following Salvage Therapy in Primary Refractory Peripheral T-Cell Lymphoma (PTCL)

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Functional Analyses of V-Atpase Mutations in Follicular Lymphoma

Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only